Aeglea BioTherapeutics - AGLE Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aeglea BioTherapeutics in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AGLE shares.
View AGLE analyst ratings or view top-rated stocks.

5 Wall Street analysts have issued twelve-month target prices for Aeglea BioTherapeutics' shares. Their AGLE share price forecasts range from $1.00 to $3.00. On average, they anticipate the company's share price to reach $1.88 in the next twelve months. This suggests a possible upside of 267.6% from the stock's current price.
View analysts price targets for AGLE or view top-rated stocks among Wall Street analysts.

Aeglea BioTherapeutics' stock was trading at $0.4499 at the beginning of the year. Since then, AGLE stock has increased by 13.4% and is now trading at $0.51.
View the best growth stocks for 2023 here.

Aeglea BioTherapeutics saw a decline in short interest in the month of January. As of January 15th, there was short interest totaling 604,200 shares, a decline of 39.6% from the December 31st total of 1,000,000 shares. Based on an average daily trading volume, of 1,950,000 shares, the days-to-cover ratio is currently 0.3 days.
View Aeglea BioTherapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 14th 2023.
View our AGLE earnings forecast.

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) announced its quarterly earnings results on Thursday, November, 3rd. The biotechnology company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.05. The biotechnology company had revenue of $0.17 million for the quarter, compared to analyst estimates of $0.63 million. Aeglea BioTherapeutics had a negative net margin of 1,471.82% and a negative trailing twelve-month return on equity of 114.95%.

3 employees have rated Aeglea BioTherapeutics Chief Executive Officer Anthony Quinn on Glassdoor.com. Anthony Quinn has an approval rating of 100% among the company's employees. This puts Anthony Quinn in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aeglea BioTherapeutics investors own include Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Kura Oncology (KURA), Aduro Biotech (ADRO), Axsome Therapeutics (AXSM), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX) and Dicerna Pharmaceuticals (DRNA).

(AGLE) raised $60 million in an IPO on Thursday, April 7th 2016. The company issued 3,500,000 shares at a price of $16.00-$18.00 per share. UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Needham & Company was co-manager.

Aeglea BioTherapeutics trades on the NASDAQ under the ticker symbol "AGLE."

Shares of AGLE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AGLE stock can currently be purchased for approximately $0.51.

Aeglea BioTherapeutics (NASDAQ:AGLE) has a market capitalization of $31.37 million and generates $18.74 million in revenue each year. The biotechnology company earns $-65,800,000.00 in net income (profit) each year or ($1.14) on an earnings per share basis.

The company employs 101 workers across the globe.

Aeglea BioTherapeutics' mailing address is 805 LAS CIMAS PARKWAY SUITE 100, AUSTIN TX, 78746. The official website for the company is www.aegleabio.com. The biotechnology company can be reached via phone at (512) 942-2935, via email at investors@aegleabio.com, or via fax at 512-872-5121.